Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Ticker
$ARCT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
175
ISIN
US03969T1097
Website
ARCT Metrics
BasicAdvanced
$391M
-
-$2.52
2.37
-
Price and volume
Market cap
$391M
Beta
2.37
52-week high
$25.54
52-week low
$8.04
Average daily volume
455K
Financial strength
Current ratio
5.643
Quick ratio
4.686
Long term debt to equity
16.678
Total debt to equity
18.249
Profitability
EBITDA (TTM)
-78.642
Gross margin (TTM)
-22.83%
Net profit margin (TTM)
-47.47%
Operating margin (TTM)
-57.13%
Effective tax rate (TTM)
0.54%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-13.67%
Return on equity (TTM)
-27.40%
Valuation
Price to revenue (TTM)
2.714
Price to book
1.67
Price to tangible book (TTM)
1.67
Price to free cash flow (TTM)
-4.338
Free cash flow yield (TTM)
-23.05%
Free cash flow per share (TTM)
-332.16%
Growth
Revenue change (TTM)
15.38%
Earnings per share change (TTM)
-37.27%
3-year revenue growth (CAGR)
110.17%
3-year earnings per share growth (CAGR)
-30.56%
What the Analysts think about ARCT
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
Bulls say / Bears say
Arcturus Therapeutics reported a reduction in net loss for Q3 2024, with a net loss of $6.9 million compared to $16.2 million in Q3 2023, indicating improved financial performance. (businesswire.com)
The company's operating expenses decreased by 18.7% in Q3 2024 compared to Q3 2023, reflecting effective cost management strategies. (businesswire.com)
Arcturus has a strong cash position with $237 million in cash and cash equivalents as of September 30, 2024, providing financial stability for future operations. (businesswire.com)
Total revenue for Q3 2024 decreased by 7.7% compared to Q3 2023, indicating potential challenges in revenue growth. (businesswire.com)
Collaboration revenue declined by 10.5% in Q3 2024 compared to Q3 2023, suggesting possible issues in partnership performance. (businesswire.com)
The company's accumulated deficit increased to $418.8 million as of September 30, 2024, reflecting ongoing financial challenges. (businesswire.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ARCT Financial Performance
Revenues and expenses
ARCT Earnings Performance
Company profitability
ARCT News
AllArticlesVideos
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Business Wire·4 days ago
Arcturus Therapeutics to Attend Upcoming Investor Conferences
Business Wire·4 weeks ago
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $391M as of June 27, 2025.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of June 27, 2025.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.